Title : Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib.

Pub. Date : 2022 Apr

PMID : 35023360






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conclusion: Sorafenib effectiveness was promising for IMDC intermediate risk, particularly Int-1, warranting further investigation. Sorafenib Wnt family member 1 Homo sapiens